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The syndrome of heart failure (HF) is the clinical manifestation of diverse underlying cardiac and noncardiac comorbidities, resulting in a heterogeneous patient population ranging from stable and ambulatory to decompensated and hospitalized. 2 Among patients recently hospitalized for worsening HF, the mortality and readmission rates approach 27% and 44%, respectively, at 1 year. 3 Despite this dismal prognosis, no specific disease-modifying therapy has been shown convincingly to improve post-discharge outcomes. 3 HF and type 2 diabetes mellitus (T2DM) are the two great pandemics of contemporary practice. Furthermore, patients with HF and concomitant T2DM are at increased risk and may have a unique pathophysiology including hemodynamic and neurohormonal abnormalities. 4 In the most recent pan-European registry, T2DM was found to be an independent predictor of death among ambulatory patients with heart failure with a reduced ejection fraction (HFrEF). 5 Furthermore, in a recent meta-analysi, 6 T2DM was more commonly found in the group of ambulatory HFrEF patients who do not improve ejection fraction over time as result of evidence-based interventions. In contrast, among patients hospitalized for acute HF, although the increased risk of morbidity and mortality conferred by known diabetic status is well established, 7, 8 the risk associated with newly diagnosed prediabetes and T2DM remains controversial. In addition, it is not entirely clear whether elevated blood glucose level in acute HF is a marker for risk or a mediator of adverse outcomes. In a large international cohort of acute HF patients, blood glucose concentrations at presentation were powerful prognostic indicators for short-term mortality even after adjusting for diabetes status, systolic function and other traditional risk factors. 9 However, the association between the full spectrum of dysglycemia and long-term outcomes after hospitalization for acute HF has not been well studied. Three randomized control trials (RCTs) [10] [11] [12] have addressed the prevalence and prognostic value of post-hoc characterization of glycemic abnormalities (i.e. prediabetes and newly diagnosed T2DM) but these studies were restricted to stable ambulatory HF patients.
In this issue of the journal, Pavlovic´et al. 1 present data from a prospective cohort study enrolling 150 patients hospitalized for worsening HFrEF and New York Heart Association functional class II-III symptoms. Based on fasting plasma glycemia and a standard 2-hour oral glucose tolerance test, patients were classified as: normoglycemic, prediabetes, and newly diagnosed T2DM. All patients were prospectively followed and outcomes, including all-cause and cardiovascular mortality, were reported at 1 year. Survival analysis was reported separately for patients with prediabetes and newly diagnosed T2DM. The Cox proportional hazard models were used to estimate the hazard ratios (HRs) for all-cause and cardiovascular mortality in patients with prediabetes and T2DM, with normoglycemic patients serving as the reference group. Cox regression models were adjusted for clinically relevant variables found to be significant on univariate analysis.
The investigators found that among hospitalized HFrEF patients, dysglycemia was common, prediabetes and T2DM, respectively, were diagnosed in 43% and 19% of patients. Furthermore, dysglycemia, compared with normoglycemia, during hospitalization was associated with a graded increased risk of all-cause and cardiovascular mortality compared with normoglycemia, with the highest risk of death observed in patients with newly diagnosed T2DM. The adjusted risk of all-cause mortality was significantly increased in patients with prediabetes (HR 2.6, 95% confidence interval (CI) 1.1-6.3; P ¼ 0.040) and T2DM (HR 5.3, 95% CI 1.7-15.3; P ¼ 0.023) compared with normoglycemic patients. The results for cardiovascular mortality are in the same direction, both prediabetes (HR 2.9, 95% CI 1.1-7.9; P ¼ 0.041) and T2DM (HR 9.7, 95% CI 2.9-36.7; P ¼ 0.018) being independently associated with increased risk when compared to patients without glycemic abnormalities. In sensitivity analyses, there were no interactions between dysglycemia and adverse outcomes with gender (i.e. male vs. female) nor HF etiology (i.e. ischemic vs. non-ischemic).
Reporting separately prediabetes and newly diagnosed T2DM is one of the most important strengths of the data. 1 To the best of our knowledge, this is the first study to report the prevalence of prediabetes in a real-life observational cohort of consecutive patients hospitalized for worsening HF. Previously, three RCTs enrolling HFrEF patients [10] [11] [12] have reported a lower prevalence of prediabetes, but all of these studies included ambulatory HF patients (Figure 1) . Furthermore, although in acute HF the increased long-term risk related to T2DM is well known, the risk associated with prediabetes has not previously been studied. The results of the present analysis are congruent with the CHARM 10 and PARADIGM-HF 12 trials, which found that patients with prediabetes were at increased risk of mortality. However, the relationship between prediabetes and adverse outcomes, although statistically significant, is only a correlation that may be hypothesis generating, but does not represent a clear cause-effect mechanistic pathway and the underlying etiology must be further elucidated. The most commonly invoked pathophysiological mechanism is insulin resistance, because the heart is an insulin-responsive organ, insulin resistance correlates with the clinical severity of HF and may cause deleterious changes in cardiac structure and function. 13 However, the exact mechanisms of insulin resistance in acute HF are unknown, and multiple pathways have been implicated in the pathophysiology of insulin resistance in acute HF, such as sympathetic overdrive, release of proinflammatory cytokines, altered adipokines, and/or endothelial dysfunction. 14, 15 In addition, hyperglycemia may also directly promote a number of direct harmful effects at the myocyte level including deranged calcium metabolism, cellular apoptosis, and/or progressive remodeling. 8, 16 However, the optimal strategy for glycemic control in patients with acute HF is controversial 17 because tight glycemic control, investigated in GLUCONTROL 18 and NICE-SUGAR, 19 was not associated with improved outcomes in critically ill patients.
These findings raise questions about the potential role of screening for prediabetes and treatment targeted at correcting dysglycemia in patients hospitalized for worsening HF. This is an important issue, because distinct from T2DM, which represents an actionable treatment target, prediabetes is a clinical entity which although highly prevalent has no recommended treatment beyond lifestyle modification. In addition, despite the existence of a significant association between prediabetes and adverse clinical outcomes in patients hospitalized for worsening HF, no recommendations to identify treatment-specific glycemic goals have been definitively established for patients with known T2DM. 20 Although specifically mentioned by the authors, 1 improving glycemic control through aerobic exercise training and/or pharmacotherapy (i.e. salcubitril/valsartan) were not specifically evaluated in RCTs enrolling worsening HFrEF patients with concomitant prediabetes. In fact, patients hospitalized for HF with prediabetes have a high risk of all-cause and cardiovascular mortality and currently there is no confirmed glycemic therapy capable of altering the natural history of the disorder.
In conclusion, Pavlovic´and colleagues 1 should be commended for investigating the epidemiology and prognosis of dysglycemia following admission for worsening HF. Patients with worsening HF and impaired glycemic control represent a highly prevalent patient population, and future RCTs enrolling patients with HFrEF and the full gamut of dysglycemic phenotypes are encouraged to refocus and differentially investigate the efficacy, safety, and tolerability in HF patients with concomitant prediabetes or diabetes. Although, in patients with T2DM, treatment with sodium-glucose co-transporter type 2 (SGLT2) inhibitors was associated with a significant decrease in all-cause mortality and HF readmissions, 21 further research should explore this effect in the larger group of patients with diverse dysglycemic phenotypes. Two ongoing trials, EMPEROR-REDUCED 22 and DAPA-HF, 23 enrolling HFrEF patients irrespective of T2DM, are investigating the role of the SGLT2 inhibitors, in addition to guideline-directed medical therapy, across the broader spectrum of dysglycemia.
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